Overview
In today’s digital world it is increasingly hard for pharmaceutical companies to successfully differentiate new brands based on their target product profile alone.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh